Fingerprint
Dive into the research topics of 'Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study)'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically